Maxim Yakimov
Papers
1
Total Citations
37
H-Index
1
About
Maxim Yakimov is a pioneering figure in theranostics and nuclear oncology, with a focused expertise in developing targeted radionuclide therapies for prostate cancer. His most impactful work centers on the innovative application of 177Lu-PSMA-I&T, a radioligand therapy, in the neoadjuvant setting. In his landmark single-arm Phase 1 trial, Yakimov demonstrated the feasibility and safety of administering this treatment to patients with high-risk prostate cancer prior to radical prostatectomy—a groundbreaking approach that could reshape surgical paradigms. This study, which has garnered 37 citations, represents a critical step toward integrating molecular radiotherapy into early-stage disease management, moving beyond its traditional use in metastatic castration-resistant prostate cancer. Yakimov’s contributions are notable for bridging the gap between systemic radionuclide therapy and localized surgical intervention, offering a potential pathway to improve pathological responses and long-term outcomes. His work is highly cited within the field of theranostics, reflecting its influence on ongoing clinical trials and translational research. For students and researchers, Yakimov exemplifies how targeted nuclear medicine can be strategically deployed to enhance curative-intent treatments.
Research Focus
Key Achievements
Top Papers
- 1